Results of the RESPECT trial presented at TCT 2012

October 25, 2012

A clinical trial indicates that using an investigational medical device to close a PFO, or "hole in the heart," may be superior to medical management alone in the prevention of a repeated stroke. Results of the RESPECT trial were presented at the 24th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium. Sponsored by the Cardiovascular Research Foundation (CRF), TCT is the world's premier educational meeting specializing in interventional cardiovascular medicine.

A PFO (patent foramen ovale) is a flap-like opening between the left and right upper chambers (atria) of the heart, which typically fuses shut after birth. In approximately one in four people, the opening does not fuse shut and in some cases, a blood clot may pass through the PFO and potentially travel to the brain causing an ischemic stroke. It is estimated that PFO rates are three times higher in the patient population with , or stroke without an overt source. However, to date, no has demonstrated superiority of PFO closure over standard for secondary , despite there being observational data suggesting a possible benefit.

RESPECT was a prospective, randomized (1:1), multi-center trial designed to evaluate whether PFO closure with the AMPLATZER PFO Occluder is superior to the current standard medical treatment in the prevention of (a second stroke). Made of wire mesh, the investigational device is inserted into the PFO through a catheter to seal the passageway between the left and right atria.

A total of 980 patients were enrolled over eight years. Patients diagnosed with a cryptogenic stroke and PFO (age 18-60) were randomized to either the investigational device group or the medical therapy group within 270 days of the stroke. Forty-nine percent of the patients had a large stroke as the qualifying stroke event. The average age in the study was 46 and patients were otherwise generally healthy.

Statistics from the RESPECT trial:

  • Two year events rates were low in both the device and medically treated groups
  • 1.6 percent vs. 3.0 percent respectively
  • All primary events were non-fatal, recurrent ischemic strokes
  • The clinical risk reduction of stroke using the device ranged from 46.6 percent to 72.7 percent compared to medical management alone, depending on the analysis population being assessed
  • Among the intent-to-treat analysis population, this reduction achieved borderline statistical significance
  • In per-protocol and as-treated analyses, the reductions were statistically significant
  • Serious adverse event (SAE) rates did not differ between the device and medical groups
  • 23.0 percent vs. 21.6 percent respectively
  • Medical therapy included one of four regimens:
  • Warfarin (25.2 percent)
  • Aspirin (46.5 percent)
  • Clopidogrel (14.0 percent)
  • Aspirin combined with dipyridamole (8.1 percent)
  • Aspirin combined with clopidogrel (6.3 percent)
  • The total incidence of atrial fibrillation was not significantly different between the device and medical group
  • 3.0 percent vs. 1.5 percent respectively
  • No device related thrombus, erosion, or embolization was observed
  • There were no study-related deaths

"In patients between 18 and 60 years old with cryptogenic ischemic stroke and PFO, the totality of evidence from RESPECT demonstrates that PFO closure with the AMPLATZER PFO Occluder provides evidence of benefit over medical management alone, with very low device and procedure-related risks," said lead investigator John D. Carroll, MD. Dr. Carroll is Professor of Medicine, Co-Director of the Cardiac and Vascular Center, and Director of Interventional Cardiology at the University of Colorado.

"The optimal secondary prevention strategy following a cryptogenic ischemic stroke in patients who are found to have a PFO has been unknown. This need to know is particularly intense for young stroke patients who have no or minimal traditional risk factors for , yet face a risk of recurrent for many decades. RESPECT makes progress in both removing the "unknown" or cryptogenic cause of some strokes and providing high quality data from a large, long-term randomized trial."

Explore further: Study shows PFO closure may be superior to medical therapy in preventing stroke

Related Stories

Study shows PFO closure may be superior to medical therapy in preventing stroke

October 25, 2012
Results of a large-scale, randomized clinical trial called RESPECT revealed that patent foramen ovale (PFO) closure may be superior to medical therapy in preventing recurrent stroke, according to a presentation of findings ...

Study finds expensive procedure no more effective than medical therapy to prevent strokes

March 14, 2012
A catheter procedure that closes a hole in patients' hearts was no more effective than medical therapy in preventing recurrent strokes, according to a new study published in the March 15 issue of the New England Journal of ...

Recommended for you

Could this protein protect people against coronary artery disease?

November 17, 2017
The buildup of plaque in the heart's arteries is an unfortunate part of aging. But by studying the genetic makeup of people who maintain clear arteries into old age, researchers led by UNC's Jonathan Schisler, PhD, have identified ...

Raising 'good' cholesterol fails to protect against heart disease

November 16, 2017
Raising so-called 'good' cholesterol by blocking a key protein involved in its metabolism does not protect against heart disease or stroke, according to a large genetic study of 150,000 Chinese adults published in the journal ...

New model estimates odds of events that trigger sudden cardiac death

November 16, 2017
A new computational model of heart tissue allows researchers to estimate the probability of rare heartbeat irregularities that can cause sudden cardiac death. The model, developed by Mark Walker and colleagues from Johns ...

Popular e-cigarette liquid flavorings may change, damage heart muscle cells

November 16, 2017
Chemicals used to make some popular e-cigarette liquid flavorings—including cinnamon, clove, citrus and floral—may cause changes or damage to heart muscle cells, new research indicates.

Possible use for botulinum toxin to treat atrial fibrillation

November 16, 2017
From temporarily softening wrinkles to easing migraines, botulinum toxin has become a versatile medical remedy because of its ability to block nerve signals that can become bothersome or risky.

Proteome of the human heart mapped for the first time

November 15, 2017
A healthy heart beats about two billion times during a lifetime, thanks to the interplay of more than 10,000 proteins. Researchers from the Max Planck Institute of Biochemistry (MPIB) and the German Heart Centre at the Technical ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.